Clinical trial
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
NCT00286806 · Ascenta Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00286806 |
|---|---|
| Title | A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer |
| Official title | An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer (HRPC) and Rising Prostate Specific Antigen (PSA) Levels Who Have Not Received Prior Chemotherapy |
| Lead sponsor | Ascenta Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hormone Refractory Prostate Cancer |
| Intervention type | Drug |
| Interventions | AT-101 |
| Enrollment | 27 |
| Start date | Dec 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Feb 6, 2006 |
| Last update posted | Aug 24, 2010 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: